All In Biotech

Drug Trial Radar · NCT04179604

Spanish Randomized Clinical Trial to Compare Levosimendan Versus Placebo in Postoperative Cardiac Surgery (SPARTANS)

Rationale and Design of a Multicenter Randomized Trial of Levosimendan to Reduce Low Cardiac Output Syndrome in Low Ejection Fraction (≤ 35%) Cardiac Surgery Patients. Spanish Randomized Clinical Trial on Levosimendan (SPARTANS Study)

Last checked: Nov 19, 2026Latest source record: Jul 24, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

300

Planned (sponsor's estimate)

Start

Jun 17, 2020

Primary completion

Jan 2022

Study completion Dec 2022

Sponsor

Lead sponsor
María de los Ángeles Tena PajueloAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Orion Corporation, Orion Pharma; Canary Foundation; Hospital Universitario de Gran Canaria Doctor Negrín; CRO TRIDE Asesores SL; QBE Europe SA/NV
First posted
Nov 27, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Low cardiac output Syndrome (LCOS) is a complication that appears in approximately 20% of cardiac surgeries with extracorporeal circulation. LCOS is associated with increased mortality, delayed recovery and prolonged hospital stay. The Spanish Randomized Clinical Trial on Levosimendan (brand name: Sindax) (SPARTANS) aims to demonstrate the effectiveness of the preoperative use of Levosimendan in reducing LCOS in patients with poor left ventricle ejection fraction (LVEF) undergoing elective cardiac surgery. SPARTANS study is a multicenter, randomized triple-blind, placebo-controlled trial. 300 patients with LVEF ≤ 35%, undergoing elective cardiac surgery will be recruited from 9 Spanish hospitals and randomized into two groups: Preoperative administration of levosimendan or placebo for 24 hours. The study drug will be started as a continuous infusion (0.1 µg/kg/min) at least 8 hours before surgery to complete 24h duration. The primary endpoint will be 30-day LCOS. It will be evaluated using any of the following criteria: 1\) postoperated cardiac index ≤2.0 L / min / m2, 2) a need to implant a intra-aortic balloon pump/ left ventricular assist device, 3) a vasoactive inotropic scale (VIS) \> 5.5. The secondary end-point will be composite event rate at one year including any of the following events: death from any cause, need for renal replacement therapy or dialysis and LCOS. The sample size is based on the assumption that levosimendan reduces LCOS by 50% being necessary a sample size of 300 patients to carry out the study. The Research Team of each hospital, will carry out the clinical follow-up by telephone or clinical interview of the patient according to the time intervals: 30 days and 1 year. We estimate that the total sample size of 300 patients will be reached in 2-2.5 years. In conclusion, the effectiveness of levosimendan has not yet been reported with a good evidence in cardiac surgery. The purpose of the "Spanish Randomized Clinical Trial on Sindax" (SPARTANS) trial is to evaluate the beneficial effect of preoperative use of levosimendan compared with placebo to reduce perioperative LCOS in patients undergoing cardiac surgery with poor LVEF ≤ 35%.

Conditions

  • Cardiac Output, Low

Interventions

  • LevosimendanDrug

    Levosimendan SIMDAX 2.5 mg / ml concentrate for solution for infusion. The concentrate is a clear solution, yellow or orange, for dilution before administration. A 5 ml vial contains 12.5 mg of levosimendan. The study drug infusion will start one day before surgery in an Intensive Care Unit with at least 8 hours of administration before surgery. A continuous infusion at 0.1 µg/kg/min will be administered to complete 24h duration.

  • PlacebosDrug

    Patients in the placebo group will receive a water-soluble vitamin B2 concentrate with 0.4 mg / ml sodium riboflavin phosphate to obtain the same color as the preparation of levosimendan and ethanol anhydrous 100 mg / ml to resemble the levosimendan odor, which will be administered at the same levosimendan infusion rate.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with LCOSTime frame: up to 30 days of cardiac surgery
  2. Number of Participants with LCOSTime frame: up to 30 days of cardiac surgery
  3. Number of Participants with LCOSTime frame: up to 30 days of cardiac surgery
  4. Number of Participants with LCOSTime frame: up to 30 days of cardiac surgery

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • A coruña UNIVERSITY HOSPITAL COMPLEX A CORUÑA

    A Coruña, Spain · Recruiting

  • 12 de Octubre University Hospital

    Madrid, Spain · Not yet recruiting

  • Virgen Macarena University Hospital

    Seville, Spain · Recruiting

  • Valladolid universitary Hospital

    Valladolid, Spain · Recruiting

  • GERMANS TRIAS I PUJOL DE BADALONA university Hospital

    Badalona, Barcelona, Spain · Not yet recruiting

  • Doctor Josep Trueta university Hospital

    Girona, Gerona, Spain · Not yet recruiting

  • Doctor Negrin University Hospital

    Las Palmas de Gran Canaria, Gran Canarias, Spain · Recruiting

  • Puerta del Hierro University Hospital

    Majadahonda, Madrid, Spain · Not yet recruiting

  • Virgen de la Victoria University Hospital

    Málaga, Malaga, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.